News Related to Hives

Related coverage linked through entity extraction aliases.

Novartis Remibrutinib Receives Positive European Opinion, Meets Endpoint in CIndU Trial

Mar 08, 2026

Novartis announced positive European regulatory opinion for remibrutinib in chronic spontaneous urticaria and reported the drug met its primary endpoint in a Phase 3 trial for chronic inducible urticaria.

Novartis Remibrutinib Meets Phase III Endpoint in Chronic Inducible Urticaria

Feb 18, 2026

Novartis announced positive Phase III RemIND trial results for oral remibrutinib in chronic inducible urticaria, marking the first therapy to meet a Phase III primary endpoint in the condition. The company has submitted a supplemental New Drug Application to the FDA.